FTSE MIB
33.308,77 -366,33 (-1,09%) Dow Jones
39.150,33 +15,53 (+0,04%) Nasdaq
17.689,36 -32,24 (-0,18%) Nikkei 225
38.596,47 -36,53 (-0,09%) Petrolio
80,59 -0,14 (-0,17%) Bitcoin EUR
59.964,65 -176,24 (-0,29%)
BioAtla, Inc. (BCAB)
Dopo ore:
| Chiusura precedente | 1,4150 |
| Aperto | 1,4200 |
| Denaro | 1,4700 x 300 |
| Domanda | 1,5300 x 200 |
| Min-Max giorno | 1,4200 - 1,5850 |
| Intervallo di 52 settimane | 1,2400 - 4,0200 |
| Volume | |
| Media Volume | 793.101 |
| Capitalizzazione | 72,655M |
| Beta (mensile su 5 anni) | 1,07 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,4800 |
| Prossima data utili | 30 lug 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 9,75 |
GlobeNewswireBioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award
Award recognizes Dr. Short’s contribution to science innovationSAN DIEGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Jay M. Short, Ph.D., Chairman, Chief Executive Officer and Cofounder, has been chosen by The Explorers Club as a recipient of this year’s Lowell Thomas Award. Dr. Short’s a
- GlobeNewswire
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
Submitted abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer (NSCLC) to the IASLC 2023 North America Conference on Lung Cancer; KOL event planned for December 4, 2023, following conclusion of the IASLC conferenceR&D day planned for December 13, 2023, to discuss BA3071 (CAB-CTLA-4) Phase 1/2 basket trialManagement to host third quarter 2023 financial results conference call and webcast on Tuesday, November 7, 2023 at 4:30 PM Eastern Time SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Bi
- GlobeNewswire
BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will provide a corporate update and participate virtually in scheduled one-on-one investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference, to be held September 11-13, 2023. Format: Fi
